In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a distribution partner with...
Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ย Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a...
Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor models of mice implanted with biopsies from patients (PDX) NT-219โs novel...
TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- ย Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
- Orbimed, Pontifax and Arkin Holdings to deposit $3.5 million investment in Kitov in escrow- Progress facilitates the advance of activities in development of the oncology asset CM-24 TEL AVIV...
Israeli Investigation of Kitov and certain officers has been terminated TEL AVIV, Israel, Aug. 14, 2019 (GLOBE NEWSWIRE) -- ย Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a clinical-stage...
TEL AVIV, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
TEL AVIV, Israel, July 12, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (โKitovโ) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
TEL AVIV, Israel, June 27, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ๏ปฟ(โKitovโ) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class oncology therapies to overcome...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.